Skip to main content
. 2015 May 7;6(17):15250–15264. doi: 10.18632/oncotarget.3888

Figure 6. High RHOB expression in melanoma cell lines and patient melanoma biopsies predict low sensitivity to the BRAF inhibitor PLX4032.

Figure 6

A. RHOB expression in a panel of BRAF-mutant metastatic melanoma cell lines analyzed by RT-qPCR. B. The IC50 of PLX4032 in a panel of BRAF-mutant metastatic melanoma cell lines was determined by viability assay and correlated with RHOB mRNA expression. C. Example of positive and negative RHOB immunostaining in melanoma biopsies. D. Kaplan-Meier progression-free survival of 32 patients with a metastatic BRAFV600X melanoma following treatment with PLX4032 according to biopsies' RHOB staining.